Search

Your search keyword '"Coward, J."' showing total 407 results

Search Constraints

Start Over You searched for: Author "Coward, J." Remove constraint Author: "Coward, J."
407 results on '"Coward, J."'

Search Results

1. Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci

3. Effect of newly developed pigments and ultraviolet absorbers on the color change of pigmented silicone elastomer

4. 126P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) in patients (pts) with checkpoint inhibitor (CPI)-experienced advanced non-small cell lung cancer (NSCLC)

6. Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance

7. Entitäten-unabhängige Sicherheit und Wirksamkeit von Erdafitinib bei Patienten mit fortgeschrittenen soliden Tumoren mit präspezifizierten genomischen FGFR- Aberrationen (RAGNAR Interimanalyse)

10. 153P Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)

12. Developing a multimodal biosensor for remote physiological monitoring

13. Measuring wet bulb globe temperatures at point-of-exertion in worldwide UK military settings: a longitudinal observational study determining the accuracy of a portable WBGT monitor

14. 1621P Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial

21. 157P Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody, in upper gastrointestinal cancers

22. 1021O Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies

23. 1057P Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing

24. Safety and Antitumor Activity of Sitravatinib in Combination with Tislelizumab in Patients With Advanced Solid Tumors: Ovarian Cancer Cohort Data

25. Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601)

30. Phase I/II study of CTLA-4 inhibitor AGEN1884 + PD-1 Inhibitor AGEN2034 in patients with advanced/refractory solid tumors, with expansion into 2L cervical cancer and solid tumors

32. Optimax 2016 : peer observation of facilitation

33. A review of the issues surrounding incidental findings on\ud CT attenuation correction (CTAC ) images during SPECT\ud myocardial perfusion imaging

41. Lesion detection performance in an anthropomorphic chest phantom: comparative analysis of low-dose CT data on two hybrid imaging systems

44. Effect of newly developed pigments and ultraviolet absorbers on the color change of pigmented silicone elastomer.

45. An Archaeological Strip, Plan and Sample excavation at 5 Coventry Rd

47. Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance

49. An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity

Catalog

Books, media, physical & digital resources